CLINICAL EXPERIENCE WITH FIRST-LINE VRD IN PATIENTS DIAGNOSED WITH MULTIPLE MYELOMA

被引：0
|
作者：
De Miguel, Llorente Dunia [1 ]
Gil, Perez Angela [1 ]
Merchan, Munoz Beatriz [1 ]
Nuevo, Lopez Irene [1 ]
Perez, Ortega Alba [1 ]
Guillen, Garcia Helga [1 ]
Vazquez, Ramo Alejandro [1 ]
Subira, Perez Dolores [1 ]
Golbano, Lopez Nuria [1 ]
Santos, Montero Ana Belen [1 ]
Morales, Sanz Dolores [1 ]
Arbeteta, Juanis Jaime [1 ]
机构：
[1] Hosp Univ Guadalajara, Guadalajara, Spain
来源：
HAEMATOLOGICA | 2020年 / 105卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PO-026
引用
下载
收藏
页码：150 / 151
页数：2
相关论文
共 50 条
  • [1] CLINICAL EXPERIENCE WITH FIRST-LINE VRD IN MULTIPLE MYELOMA DIAGNOSTIC PATIENTS
    De Miguel Llorente, D.
    Gil Perez, A.
    Diaz Morfa, M.
    Golbano Lopez, N.
    Vazquez Ramo, A.
    Guillen Lopez, H.
    Nuevo Lopez, I
    Perez Ortega, A.
    Arbeteta Juanis, J.
    Subira Perez, D.
    Morales Sanz, D.
    Garcia Ramirez, P.
    Santos Montero, A. B.
    Herrero Martin, S.
    HAEMATOLOGICA, 2019, 104 : 194 - 195
  • [2] BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (VRD) AS FIRST-LINE TREATMENT IN PATIENTS DIAGNOSED WITH MULTIPLE MYELOMA. EXPERIENCE IN NON-CANDIDATE PATIENTS FOR HEMATOPOIETIC PROGENITOR TRANSPLANTATION
    Llorente Dunia, De Miguel
    Lopez Irene, Nuevo
    Munoz Beatriz, Merchan
    Argumanez Marta, Mora
    Perez Angela, Gil
    Ramo Alejandro, Vazquez
    Garcia Helga, Guillen
    Lopez Nuria, Golbano
    Ana Belen, Santos Montero
    Perez Dolores, Subira
    Juanis Jaime, Arbeteta
    HAEMATOLOGICA, 2021, 106 (10) : 340 - 341
  • [3] Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma
    Tandon, Nidhi
    Sidana, Surbhi
    Rajkumar, S. Vincent
    Gertz, Morie A.
    Buadi, Francis K.
    Lacy, Martha Q.
    Kapoor, Prashant
    Gonsalves, Wilson, I
    Dispenzieri, Angela
    Kourelis, Taxiarchis, V
    Warsame, Rahma
    Dingli, David
    Fonder, Arnie L.
    Hayman, Suzanne R.
    Hobbs, Miriam A.
    Hwa, Yi Lisa
    Kyle, Robert A.
    Leung, Nelson
    Go, Ronald S.
    Lust, John A.
    Russell, Stephen J.
    Kumar, Shaji K.
    BLOOD ADVANCES, 2019, 3 (05) : 744 - 750
  • [4] Outcomes with different administration schedules of VRD as first-line therapy in multiple myeloma: a retrospective analysis
    Cook, Joselle
    Sidana, Surbhi
    Gonsalves, Wilson
    Gertz, Morie A.
    Buadi, Francis
    Lacy, Martha
    Kapoor, Prashant
    Dispenzieri, Angela
    Kourelis, Taxiarchis
    Warsame, Rahma
    Dingli, David
    Fonder, Amie
    Hayman, Suzanne
    Hobbs, Miriam
    Hwa, Yi Lisa
    Kyle, Robert
    Leung, Nelson
    Go, Ronald
    Rajkumar, S. Vincent
    Kumar, Shaji
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E203 - E203
  • [5] Characteristics and Outcomes of Non-Transplanted Patients with Newly Diagnosed Multiple Myeloma (NDMM) Initiating Treatment with Bortezomib, Lenalidomide, and Dexamethasone (VRd) As First-Line of Therapy
    Medhekar, Rohan
    Ran, Tao
    Fu, Alex Z.
    Patel, Sharmila
    Kaila, Shuchita
    BLOOD, 2021, 138 : 3782 - +
  • [6] BORTEZOMIB IN THE FIRST-LINE TREATMENT OF MULTIPLE MYELOMA: THE EXPERIENCE OF A CENTER
    Mendes, M. J.
    Ferreira, G.
    Saturnino, H.
    Duarte, M.
    Almeida, J. C.
    Arajo, L. F.
    Ribeiro, M. L.
    HAEMATOLOGICA, 2015, 100 : 735 - 735
  • [7] First-line bortezomib benefits patients with multiple myeloma
    Meletios A. Dimopoulos
    Evangelos Terpos
    Nature Reviews Clinical Oncology, 2009, 6 : 683 - 685
  • [8] First-line treatment of multiple myeloma
    Breitkreutz, I
    Raab, M.
    Goldschmidt, H.
    INTERNIST, 2019, 60 (01): : 23 - 33
  • [9] Clinical efficacy of thalidomide containing regimens as a first-line therapy in patients with multiple myeloma
    Kim, Y. K.
    Lee, J. J.
    Lee, S. R.
    Shim, H. J.
    Ahn, J. S.
    Yang, D. H.
    Cho, S. H.
    Chung, I. J.
    Kim, D. H.
    Sohn, S. K.
    Shin, H. J.
    Kim, H. J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 177 - 177
  • [10] HEMATOLOGY First-line bortezomib benefits patients with multiple myeloma
    Dimopoulos, Meletios A.
    Terpos, Evangelos
    NATURE REVIEWS CLINICAL ONCOLOGY, 2009, 6 (12) : 683 - 685
12345